Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
RESEARCH TOOLSreports
Arvinas Holding Company (ARVN) Stock Price & Analysis
766 Followers
ARVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.57 - $53.08
Previous Close$32.68
Volume537.15K
Average Volume (3M)731.22K
Market Cap
$2.24B
Enterprise Value$978.55M
Total Cash (Recent Filing)$1.26B
Total Debt (Recent Filing)$3.20M
Price to Earnings (P/E)-5.5
Beta1.63
Next Earnings
Aug 06, 2024EPS Estimate
-$1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.93
Shares Outstanding68,431,891
10 Day Avg. Volume642,668
30 Day Avg. Volume731,224
Standard Deviation0.39
R-Squared0.07
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.33
Price to Sales (P/S)28.49
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.47
Enterprise Value/Gross Profit12.47
Enterprise Value/Ebitda-2.60
Forecast
1Y Price Target
$65.31Price Target Upside99.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Arvinas Holding Company News
Bulls Say, Bears Say
Bulls Say
Clinical Trial DataThe combination of vepdegestrant and palbociclib demonstrates a consistent clinical benefit rate in heavily pretreated patients, showcasing the potential for efficacy in early treatment settings.
Financial PositionThe company's robust financials, with significant cash reserves, provide a stable foundation for continued operations and reduced financial risk.
Strategic PartnershipsThe strategic outlicensing of ARV-766 to Novartis is a positive move, allowing the company to concentrate on advancing its early-stage pipeline and adding value for shareholders.
Bears Say
Clinical Trial DataWhile CBR (~85%) was numerically higher than vepdegestrant + palbo combo (~63%), the data does not look differentiated versus ARVN's at this time.
Competitive LandscapeCompetitor data in 2024 could impact ARVN's market position, with LLY's imlunestrant presenting potential competition.
Financial PerformancePrice Target decreased due to dilution following a private placement.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $13.57 and its highest was $53.08 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Currently, no data Available
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Aug 06, 2024 which is in 80 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on May 07, 2024. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.42 by $0.45.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -$1.12.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 68,431,890 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.42. Following the earnings report the stock price went up 6.417%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Among the largest hedge funds holding Arvinas Holding Company’s share is New Leaf Venture Partners, L.L.C.. It holds Arvinas Holding Company’s shares valued at 53M.
---
Arvinas Holding Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.31 (99.85% Upside)
$65.31 (99.85% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 924.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $484.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.86%
12-Months-Change
Fundamentals
Return on Equity
-63.32%
Trailing 12-Months
Asset Growth
3.13%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
---
ARVN Stock 12 Month Forecast
Average Price Target
$65.31
▲(99.85% Upside)
Technical Analysis
Best Analysts Covering ARVN
1 Year
1 Year Success Rate
9/13 ratings generated profit
1 Year Average Return
+26.19%
initiated a buy rating 11 days ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +26.19% per trade.
---